Novartis confident of Zolgensma supply, calls $2 million price 'speculation'

ZURICH (Reuters) - Novartis is sure it has satisfactory generation limit with regards to its Zolsgensma quality treatment should controllers this month endorse the medication for various types of the hereditary illness spinal strong decay, the Swiss drugmaker said on Wednesday.

"At last, they (the U.S. Nourishment and Drug Administration) should say something regarding precisely where we arrive on the mark," Novartis' David Lennon, who heads the Zolgensma program, told experts on a call. "We stay exceptionally sure around our capacity to supply the market under a scope of situations for what the FDA may give us as far as endorsement."

Lennon additionally said a media report this week recommending Zolgensma would be estimated at $2 million for every patient was "finished hypothesis." Novartis has said it is thinking about a range between $1.5 million and $5 million.

(Announcing by John Miller; altering by Brenna Hughes Neghaiwi)